Therapeutic evaluation of intralesional measles, mumps and rubella vaccine in palmoplantar warts
Keywords:Warts, Immunotherapy, MMR vaccine
Background: Warts are common viral infections of the skin caused by human papilloma virus. Most of the treatment modalities for common warts remain unsatisfactory. Immunotherapy has become one of the important therapeutic modality. This study was conducted to evaluate the efficacy of intralesional measles, mumps and rubella (MMR) vaccine immunotherapy in palmoplantar warts.
Methods: 60 patients of various age groups and both sexes who have single or multiple palmoplantar warts not on any other concurrent systemic or topical therapy were randomly included for the study. Patients with other types of warts, signs of other infection, pregnancy, lactation and immunosuppression were excluded from the study. MMR Vaccine was injected intralesionally at 2 week intervals until complete clearance or for a maximum of 3 treatments. The outcome in terms of treatment relapse, recurrences and adverse effects were evaluated.
Results: Only 54 patients completed the study and 41 (75.9%) of them showed complete response and 13 (24%) of them showed partial or no response.
Conclusions: Intralesional MMR vaccine therapy appears to be a safe and effective treatment option with no significant adverse effects and low recurrence.
Leto MGP, Santos GF, Porro AM, Tomimori J. Human papilloma virus infection: etiopathogenesis, molecular biology and clinical manifestations. An Bras Dermatol. 2011;86(2):306-17.
Castellsague X, Cohet C, Puig-Tintore LM. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health. 2009;19:106-10.
Singh S, Chouhan K, Gupta S. Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereal Leprol. 2014;80:509-14.
Bruggink SC, de Koning MN, Gusseklooa J, Egberts PF, Ter Schegget J, Feltkamp MC, et al. Cutaneous wart-associated HPV types: Prevalence and relation with patient characteristics. J Clin Virol. 2012;55(3):250-5.
Saini P, Mittal A, Gupta LK. Intralesional mumps, measles and rubella vaccine in the treatment of cutaneous warts. Indian J Dermatol Venereal Leprol. 2016;82(3):343-4.
Bacelieri R, Johnson SM. Cutaneous warts: an evidence–based approach to therapy. Am Fam Physician. 2005;72:647-52.
Thappa DM, Chiramel MJ. Evolving role of immunotherapy in the treatment of refractory warts. Indian Dermatol Online J. 2016;7(5):364-70.
Mohammed El-Khalawany, Shaaban D, Aboeldahab S. Immunotherapy of warts. Egypt J Dermatol Venereol. 2015;35:1-13.
Naseem R, Aamir S. The efficacy of intralesional MMR antigen in the treatment of common warts. PJMHS. 2013;7(4):1130-3.
Nofal A, Nofal E. Intralesional immunotherapy of common warts: successful treatment with MMR vaccine. J Eur Acad Dermatol Venereol. 2010;24:1166-70.
Gamil H, Elgharib I, Nofal A, Abd-Elaziz T. Intralesional immunotherapy of plantar warts. Report of a new antigen combination. J Am Acad Dermatol. 2010;63:40-3.
Kus S, Ergun T, Gun D, Akin O. Intralesional tuberculin for treatment of refractory warts. Saudi Med J. 2008;29:589-93.
Clifton MM, Johnson SM, Robertson PK, Kincannon J, Horn TD. Immunotherapy for recalcitrant warts in children using intralesional mumps or candida antigens. Pediatr Dermatol. 2003;20:268-71.
Chandrashekar L. Intralesional immunotherapy for the management of warts. Indian J Dermatol Venereol Leprol. 2011;77(3):261-3.
Dhope A, Madke B, Singh AL. Effect of measles, mumps rubella vaccine in treatment of common warts. Indian J Drugs Dermatol. 2017;3:14-9.
Raju J, Swamy AV, Swamy BLN, Raghavendra KR. Intralesional measles, mumps and rubella vaccine- an effective therapeutic tool in the treatment of wart. J Evidence Based Med Healthcare. 2015;2(50):8548-51.
Munnangi P, Kishore KLP, Devi VN. Comparative study between intralesional MMR and intralesional BCG in the treatment of verruca vulgaris. IOSR J Dent Med Sci. 2018;17(2):44-50.